Sunita Adhikari
Primary Care · Woodbridge, VANPI 1366138521
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,630 and has fallen 57.7% since, to $689 in 2025.
Across 126 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$674
- AstraZeneca$341
- Lilly USA, LLC$321
- Xeris Pharmaceuticals, Inc.$315
- AbbVie$223
- Amgen$207
- plus $835 from 16 others
What the payments were for
- Food & beverage$2,917100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $674 |
| AstraZeneca | 19 | $341 |
| Lilly USA, LLC | 15 | $321 |
| Xeris Pharmaceuticals, Inc. | 4 | $315 |
| AbbVie | 12 | $223 |
| Amgen | 10 | $207 |
| Exact Sciences | 8 | $183 |
| Bayer | 5 | $103 |
| Corcept Therapeutics | 3 | $79 |
| Novartis | 4 | $72 |
| GSK | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Boehringer Ingelheim | 2 | $47 |
| Merck | 3 | $46 |
| Pfizer | 2 | $43 |
| Novavax Inc | 1 | $29 |
| Boston Scientific | 1 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$281
- Wegovy$125
- Ozempic$111
How this compares
$2,917 in reported general payments places this provider in the 85th percentile of 142 primary care providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $40,818 |
| OzempicSemaglutide | 22 | $38,588 |
| JanuviaSitagliptin Phosphate | 21 | $32,104 |
| TrulicityDulaglutide | 17 | $26,140 |
| EliquisApixaban | 12 | $20,575 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,953 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,534 |
| SynthroidLevothyroxine Sodium | 22 | $1,443 |
| Atorvastatin Calcium | 114 | $1,354 |
| Rosuvastatin Calcium | 134 | $1,221 |
| Bupropion XlBupropion Hcl | 14 | $991 |
| Olmesartan Medoxomil | 51 | $966 |
| Levothyroxine Sodium | 76 | $797 |
| Ezetimibe | 20 | $713 |
| Irbesartan | 23 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $47 | $40,81826 claims |
| Novo NordiskOzempic | $674 | $38,58822 claims |
| MerckJanuvia | $46 | $32,10421 claims |
| Lilly USA, LLCTrulicity | $321 | $26,14017 claims |
| PfizerEliquis | $43 | $20,57512 claims |
| AbbVieSynthroid | $223 | $1,44322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 primary care providers in Virginia.
Other primary care in Woodbridge
- Rebecca GrinsellRichmond$12K
- Jennifer CampbellNewport News$8K
- Tien MaAnnandale$7K
- Michael CogginAshland$7K
- Erin StewartFredericksburg$6K
- Lawanda WoodNorfolk$6K
- Sara WeaverDanville$5K
- Luis Rivera PenaFalls Church$4K
- Erika RobinsonFredericksburg$4K
- Haley SwansonVirginia Beach$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.